Insider Trading History of Sigal Charles Elliott

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Sigal Charles Elliott since 2016. This trader's CIK number is 1661908. At the time of last reporting, Sigal Charles Elliott was the Director of Vir Biotechnology, Inc.. (stock ticker symbol VIR). Also see all insider trading activities at Vir Biotechnology, Inc..

Note that in the past Sigal Charles Elliott also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Adaptimmune Therapeutics Plc (ADAP) by Sigal Charles Elliott

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2016 ADAP 60,000 $92,100 0 $0 0 $0

Yearly summary of insider trading at Vir Biotechnology, Inc. (VIR) by Sigal Charles Elliott

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2023 VIR 5,000 $119,209 0 $0 0 $0


Insider trading activities at 2 companies by Sigal Charles Elliott:

1. Adaptimmune Therapeutics Plc (ADAP)

2. Vir Biotechnology, Inc. (VIR)

Table 1. Insider trading of Adaptimmune Therapeutics Plc (ADAP) by Sigal Charles Elliott

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2016-05-19 ADAP Buy 15,000 1.56 23,400
2016-05-18 ADAP Buy 15,000 1.55 23,250
2016-05-17 ADAP Buy 15,000 1.53 22,950
2016-05-16 ADAP Buy 15,000 1.50 22,500

Table 2. Insider trading of Vir Biotechnology, Inc. (VIR) by Sigal Charles Elliott

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2023-03-01 VIR Buy 2,500 22.73 56,815
2023-01-05 VIR Buy 2,500 24.96 62,394

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Sigal Charles Elliott (Director of Vir Biotechnology, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.